Join to View Full Profile
44 Binney Streetd1b30Danafarber Cancer InstituteBoston, MA 02115
Phone+1 617-632-5946
Fax+1 617-632-5168
Are you Dr. Cutler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Corey Cutler, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Vermont, and Florida. He is an Associate Professor at Harvard Medical.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
McGill University Faculty of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026
VT State Medical License 2023 - 2026
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 1 citationsIbrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Joseph Pidala, Jongphil Kim, Denise Kalos, Corey Cutler, Zachariah DeFilipp
Blood Advances. 2025-03-11 - Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gra...Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-03-01 - Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey
JAMA Oncology. 2025-03-01
Press Mentions
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025- FDA Approves Treatment for Chronic Graft Versus Host DiseaseSeptember 6th, 2024
- Notice of Compliance Issued Regarding Rezurock(TM) (Belumosudil Tablets)March 21st, 2023
- Join now to see all
Grant Support
- Mechanisms and Therapy of Chronic Graft-vs.-Host DiseaseDANA-FARBER CANCER INST2022–2027
